Rx Prescripttion Only-YMYL Medical Content

Erdafixen 4 mg

Erdafitinib 4mg tablets – Everest Pharmaceuticals Ltd.

Approved for adults with locally advanced or metastatic urothelial carcinoma (bladder cancer) harboring susceptible FGFR3 genetic alterations, as detected by an FDA-approved companion diagnostic, whose disease has progressed on or after at least one prior line of systemic therapy — and who have received prior PD-1/PD-L1 checkpoint inhibitor therapy.

12.1 mo

Median overall survival vs 7.8 mo with chemotherapy (THOR Phase III trial)

5.6 mo

Median progression-free survival vs 2.7 mo with chemotherapy (THOR)

45.6%

Overall response rate vs 11.5% with chemotherapy — a 4x improvement (THOR)

Only

FDA-approved FGFR inhibitor for urothelial carcinoma — full approval January 2024

Confirm FGFR3 alteration status

Requires tumor tissue or blood-based testing with an FDA-approved companion diagnostic (therascreen FGFR RGQ RT-PCR Kit or FoundationOne CDx) showing a susceptible FGFR3 mutation or fusion — found in roughly 10–20% of metastatic urothelial cancers.

Confirm prior treatment history including checkpoint inhibitor

Requires at least one prior line of systemic therapy, and prior receipt of (or ineligibility for) a PD-1/PD-L1 checkpoint inhibitor — erdafitinib is not recommended for patients who are eligible for but have not yet received checkpoint inhibitor therapy.

Baseline eye examination and phosphate level check

Ophthalmology review is required before starting — ocular toxicity (including central serous retinopathy and dry eye) is a distinctive risk. Baseline serum phosphate determines up-titration eligibility.

Discuss goals of care and monitoring requirements

Weigh the response rate and survival benefit against monthly ophthalmology visits, serum phosphate management, and avoidance of grapefruit and acid-reducing agents during treatment.

Important safety information: Erdafitinib can cause serious ocular toxicity, including central serous retinopathy (CSR) and retinal pigment epithelial detachment, which may affect vision and require treatment interruption or permanent discontinuation. Hyperphosphatemia (elevated blood phosphate) occurs in the majority of patients and requires dietary management and dose monitoring. Embryo-fetal toxicity — do not use in pregnancy. Grapefruit and proton pump inhibitors must be avoided during treatment.

Medical Oncologist Review

Board-certified oncologist · 12+ years in thoracic malignancies

“Erdafitinib gives us the first targeted option for FGFR3-altered bladder cancer — a population that until recently had to rely on chemotherapy after immunotherapy failure. The 4x response rate improvement over chemotherapy in THOR is clinically meaningful. The ocular toxicity is what I spend the most time preparing patients for, since it can develop gradually and monthly eye exams are non-negotiable on this drug.”

Content reviewed against FDA prescribing information, NCCN Guidelines v2.2024, and published Phase III trial data. Last updated June 2026.

Ready to discuss Tagrisso with your care team?

These steps help you have an informed conversation. A confirmed EGFR mutation result is the starting point for any treatment decision.

Questions to ask my healthcare provider

What questions should I ask my oncologist about starting erdafitinib?

Here are key questions to bring to your oncologist — the ophthalmology monitoring requirement and the phosphate management plan are the two areas that are most distinctive to this drug and worth understanding clearly before starting.

Before confirming erdafitinib as your treatment

Has my tumor been tested for FGFR3 alterations using an FDA-approved companion diagnostic — and which specific FGFR3 mutation or fusion was found?
Have I received prior checkpoint inhibitor (PD-1/PD-L1) therapy — and if not, why is erdafitinib being considered before that step?
What prior treatment lines have I had, and why is erdafitinib being recommended now rather than another option?
Is there a clinical trial I should know about at this point?

About the eye monitoring — the most distinctive requirement for this drug

Do I need a baseline ophthalmology examination before starting, and which type of specialist should I see?
How often will eye exams be needed during treatment — monthly?
What visual symptoms should prompt me to call immediately rather than wait for a scheduled eye exam — blurred vision, seeing halos, distorted central vision, or any sudden change?
If central serous retinopathy is detected, what happens to my treatment — is it paused, dose-reduced, or stopped permanently depending on severity?
Do I wear contact lenses, and does that matter given the dry eye side effect?

About phosphate levels and up-titration

What does “up-titration based on serum phosphate” mean in practice — how will my dose potentially change after starting?
How often will my phosphate levels be checked, especially in the first month?
What dietary changes are recommended to manage phosphate levels — are there high-phosphate foods I should reduce?
At what phosphate level would my dose need to be adjusted downward?
Will I need phosphate-binding medications, and if so, how do those interact with erdafitinib timing?

About the PPI and grapefruit restrictions

Do I currently take any proton pump inhibitors or H2 blockers for reflux or stomach protection, and what’s the plan if I do?
How strictly must I avoid grapefruit and grapefruit juice — does this include products containing grapefruit extract?

About dosing and schedule

I start at 8mg (two 4mg tablets) once daily — is there a preference for morning or evening, and does food matter?
What happens if I miss a dose or vomit shortly after taking it?
How likely is it that I’ll need a dose reduction, and does reducing from 8mg to lower doses affect how well it works?

About managing other common side effects

What mouth care routine is recommended to reduce stomatitis risk from the start?
What should I do about nail changes — are there specific nail care practices to reduce paronychia or nail separation risk?
For diarrhea, should I have anti-diarrheal medication on hand from day one?
Are there specific skin care recommendations given the dry skin and potential skin reactions?

About monitoring overall

Besides eye exams and phosphate levels, what blood tests will be done regularly — liver function, kidney function, electrolytes?
What is the scan schedule to track whether this is working, and when would we expect to see a response?

About my specific situation

Does my kidney function affect my dose or monitoring plan?
How does erdafitinib interact with my other current medications?
If I am of childbearing potential, what contraception is required and for how long after stopping?

About the longer road

If erdafitinib stops working, what would typically come next?
Are there resistance mechanisms being studied that might open clinical trial options at progression?
Are there patient assistance programs through Janssen/J&J if cost is a concern?

A practical tip: Because monthly ophthalmology visits are genuinely part of the treatment protocol — not optional follow-ups — it’s worth identifying an ophthalmologist familiar with drug-related retinal toxicity before starting, and confirming that your oncologist and eye specialist have a clear communication pathway. Finding that specialist after visual symptoms develop is harder and slower than setting up the monitoring relationship in advance.

compare with other therapies

How does FGFR3 mutation testing work for bladder cancer?

FGFR3 testing in bladder cancer has an interesting history — unlike EGFR testing in lung cancer (where testing was adopted alongside the first targeted drug), FGFR3 mutations in bladder cancer were identified and studied for years before an approved drug existed to act on them. The testing infrastructure was essentially waiting for the drug, rather than the other way around.

What’s being tested

FGFR3 (Fibroblast Growth Factor Receptor 3) is a receptor tyrosine kinase involved in cell growth and differentiation. In urothelial carcinoma, FGFR3 alterations drive tumor growth through two main mechanisms:

Point mutations — single nucleotide changes at specific positions in the FGFR3 gene that cause the receptor to be constitutively active (permanently “switched on”), even without its normal growth factor signal. The most common include S249C, R248C, G370C, Y373C, and several others — these are the “susceptible FGFR3 mutations” referred to in erdafitinib’s indication.

Gene fusions — rearrangements where part of the FGFR3 gene fuses with another gene (most commonly TACC3), creating an abnormal fusion protein that also drives uncontrolled signaling. These fusions are less common than point mutations but are equally targetable by erdafitinib.

Together, susceptible FGFR3 mutations and fusions are found in roughly 10–20% of locally advanced or metastatic urothelial carcinomas — meaning the majority of bladder cancer patients won’t have this alteration, but for those who do, it defines a targetable subgroup.

Sample source

Both tissue and blood-based testing are used:

Tumor tissue — from a biopsy or prior surgical specimen (including TURBT — transurethral resection of the bladder tumor, which is commonly how bladder cancer is initially diagnosed and staged). Archival tissue from a prior procedure is often sufficient if it’s of adequate quality.

Liquid biopsy (urine or blood) — an interesting feature of bladder cancer specifically is that tumor DNA can shed into urine, making urine-based ctDNA testing a potential non-invasive alternative or complement to tissue testing. Blood-based liquid biopsy is also used. Urine-based FGFR3 testing has been an area of active development given the accessibility and non-invasive nature of urine collection in a disease that originates in the urinary tract.

How the lab analyzes it

Two companion diagnostics are FDA-approved specifically alongside erdafitinib:

therascreen FGFR RGQ RT-PCR Kit — a PCR-based assay designed to detect specific known FGFR3 mutations and fusions from tissue samples. This was the original companion diagnostic validated with erdafitinib’s accelerated approval in 2019.

FoundationOne CDx — a comprehensive genomic profiling panel using NGS that detects FGFR3 alterations alongside hundreds of other cancer-relevant genes simultaneously. This broader panel is particularly useful when comprehensive genomic profiling is being done for treatment planning across multiple potential targets.

The PCR-based assay is faster and more targeted; NGS panels take longer but provide a complete molecular picture of the tumor that may inform other treatment decisions beyond just FGFR3.

Timeline

PCR-based FGFR3 testing typically returns results in 1–2 weeks. NGS comprehensive panels generally take 2–3 weeks. Urine-based testing, where available, can sometimes return faster given easier sample collection logistics.

What the result means for treatment

Result	What it typically means
Susceptible FGFR3 mutation detected (e.g., S249C, R248C, G370C, Y373C)	Erdafitinib is potentially indicated after prior systemic therapy including PD-1/L1
FGFR3 fusion detected (e.g., FGFR3-TACC3)	Same — erdafitinib indication covers susceptible fusions
FGFR3 alteration detected but not a “susceptible” variant	May not qualify for erdafitinib — not all FGFR3 alterations are covered by the approval
FGFR3 negative	Erdafitinib not indicated; other treatment lines considered

The “susceptible” qualification — an important nuance

Not every FGFR3 alteration detected on a genomic test qualifies a patient for erdafitinib. The FDA approval specifically covers a defined list of susceptible alterations — those that were included in the clinical trials and shown to respond. If a report shows an FGFR3 variant that isn’t on that list, it’s worth specifically asking your oncologist and the molecular pathology team whether that specific alteration falls within the approved indication, rather than assuming any FGFR3 finding automatically qualifies.

Re-testing considerations

Unlike some cancers where a single upfront test is definitive, bladder cancer is notable for its molecular heterogeneity and evolution over time — FGFR3 mutation status can differ between the primary tumor and metastatic sites, and between an early specimen and a later progression biopsy. If archival tissue was tested years ago and results were negative, re-testing on a more recent biopsy is worth discussing with your oncologist, particularly since testing methods have also improved substantially since earlier years of FGFR3 assay development.

A practical nuance

Because bladder cancer patients often have multiple prior procedures (TURBT, biopsies, cystectomy specimens), there’s usually existing tissue available for testing without requiring a new invasive procedure — which is meaningfully different from some solid tumors where re-biopsy is the only option. Asking your urologist or oncologist which existing specimen is most suitable (most recent, adequate tumor content, properly preserved) can save time compared to arranging a new biopsy when tissue may already be available in the pathology archive.

How does testing work

Why does erdafitinib cause hyperphosphatemia and how is it managed?

Hyperphosphatemia from erdafitinib is one of the most mechanistically interesting side effects we’ve encountered in this entire conversation — because unlike most drug side effects (which represent unintended toxicity), the phosphate elevation here is a direct, predictable consequence of the drug doing exactly what it’s designed to do. Understanding why it happens actually helps explain how the drug works.

The mechanism — FGFR signaling normally suppresses phosphate retention

Under normal physiology, the body maintains tight phosphate balance through a hormone called FGF23 (Fibroblast Growth Factor 23), which is produced by bone cells and acts on the kidneys to increase phosphate excretion in urine. FGF23 delivers this signal by binding to and activating FGFR receptors in the kidney — specifically a complex involving FGFR1 and a co-receptor called Klotho.

When erdafitinib inhibits FGFR signaling throughout the body — not just in tumor cells, but in normal kidney tissue too — it blocks this FGF23-FGFR signaling axis in the kidney. The result: the kidney loses the signal telling it to excrete phosphate, phosphate reabsorption increases, and serum phosphate rises.

This is an on-target, class-effect consequence of FGFR inhibition — it happens with all FGFR inhibitors to varying degrees, not just erdafitinib, and it’s mechanistically unavoidable given how the drug works.

Why phosphate levels are actually used to guide dosing

This is what makes erdafitinib unusual: because hyperphosphatemia is a predictable pharmacodynamic marker of FGFR inhibition, serum phosphate level has been used as a surrogate measure of adequate drug exposure. In the THOR trial protocol, patients who did not show sufficient phosphate elevation within the first few weeks (suggesting possible under-exposure) were eligible for dose up-titration from 8mg to 9mg daily.

So paradoxically, some degree of phosphate elevation is actually the intended signal that the drug is reaching its target — it’s managed rather than eliminated entirely.

What hyperphosphatemia means clinically

Chronically elevated phosphate can cause:

Calcification of soft tissues and blood vessels over time
Bone and joint pain
Kidney stress if severe and prolonged
Corneal and conjunctival calcium deposits (contributing to the ocular side effects)

Most cases seen with erdafitinib are manageable rather than immediately dangerous, but they require active monitoring and dietary intervention to prevent accumulation over the months of treatment.

How it’s managed — a layered approach

Dietary phosphate restriction is the first line of management. High-phosphate foods that patients are typically asked to reduce or avoid include:

Dairy products (milk, cheese, yogurt)
Processed and packaged foods containing phosphate additives (these are particularly problematic because inorganic phosphate from food additives is absorbed much more efficiently than organic phosphate from whole foods)
Nuts, seeds, and legumes in large quantities
Cola drinks (phosphoric acid content)
Organ meats

Many erdafitinib prescribing centers provide a specific dietary phosphate restriction guide as part of treatment initiation — asking for this proactively is worth doing.

Phosphate-binding medications are added when dietary restriction alone doesn’t keep phosphate within target range. These work by binding dietary phosphate in the gut before it can be absorbed, reducing the amount entering the bloodstream. Common options include calcium carbonate, sevelamer, and lanthanum carbonate — taken with meals rather than at the same time as erdafitinib, since timing matters for their effectiveness.

Dose modification — if phosphate rises above a defined threshold despite dietary and medication management, erdafitinib dose reduction or temporary interruption is the next step. The prescribing information includes specific phosphate level thresholds that guide these decisions.

Monitoring schedule

Serum phosphate is typically checked:

At baseline before starting
Every two weeks for the first month or two (the most critical period for dose up-titration decisions and catching early elevation)
Monthly thereafter once stable
More frequently if phosphate becomes elevated and management changes are being made

The connection to ocular toxicity

It’s worth noting that the phosphate-related calcification mechanism is thought to contribute to some of erdafitinib’s ocular side effects — calcium-phosphate deposits can accumulate in the cornea and conjunctiva, contributing to dry eye, eye irritation, and more serious retinal changes. This is one reason why managing phosphate levels well throughout treatment isn’t just about kidney protection — it’s also part of protecting vision over the longer term of treatment.

The practical takeaway

Hyperphosphatemia from erdafitinib is predictable, expected, and manageable — but it requires active engagement rather than passive monitoring. Starting a dietary phosphate restriction plan from day one (rather than waiting until phosphate is already elevated), having a clear threshold for when to add a phosphate binder, and knowing exactly how frequently phosphate will be checked are all worth establishing explicitly with your oncology team before the first dose, rather than developing the management plan reactively once levels rise.

Medical disclaimer: This page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Osimertinib is a prescription medication that must only be used under the supervision of a qualified oncologist. Clinical outcomes data is drawn from published Phase III trials; individual results vary. Always consult your healthcare provider and refer to the full prescribing information before making any treatment decisions. Emergency: call your local emergency services or poison control immediately if you experience serious adverse effects.